Skip to content
10-Q

Quarterly Report

UroGen Pharma Ltd. URGN

0001437749-25-033468

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 31, 2025 46.81M sh
Capex Q3 2025 · Sep 30, 2025 $272K
Capex Q3 2025 · Sep 30, 2024 $180K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$124.12M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$83.15M
Long Term Debt Q3 2025 · Sep 30, 2025 $122.11M
Long Term Debt Q3 2025 · Dec 31, 2024 $121.73M
Short Term Investments Q3 2025 · Sep 30, 2025 $63.79M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $90.04M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $171.99M
Stockholders Equity Q3 2025 · Sep 30, 2025 −$115.41M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$93.38M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$8.8M
Stockholders Equity Q3 2025 · Sep 30, 2024 $25.52M
Stockholders Equity Q3 2025 · Jun 30, 2024 $30.31M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$65.21M
Current Liabilities Q3 2025 · Sep 30, 2025 $42.24M
Current Liabilities Q3 2025 · Dec 31, 2024 $45.95M
Total Liabilities Q3 2025 · Sep 30, 2025 $300.45M
Total Liabilities Q3 2025 · Dec 31, 2024 $294.51M
Current Assets Q3 2025 · Sep 30, 2025 $168.55M
Current Assets Q3 2025 · Dec 31, 2024 $276.14M
Total Assets Q3 2025 · Sep 30, 2025 $185.05M
Total Assets Q3 2025 · Dec 31, 2024 $285.71M
Eps Basic Q3 2025 · Sep 30, 2025 −$0.69
Eps Basic Q3 2025 · Sep 30, 2025 −$2.66
Eps Basic restated Q3 2025 · Sep 30, 2024 −$0.51
Eps Basic restated Q3 2025 · Sep 30, 2024 −$2.15
Sga Expense Q3 2025 · Sep 30, 2025 $37.58M
Sga Expense Q3 2025 · Sep 30, 2025 $115.75M
Sga Expense Q3 2025 · Sep 30, 2024 $28.94M
Sga Expense Q3 2025 · Sep 30, 2024 $86.3M
Rd Expense Q3 2025 · Sep 30, 2025 $14.01M
Rd Expense Q3 2025 · Sep 30, 2025 $52.79M
Rd Expense Q3 2025 · Sep 30, 2024 $11.36M
Rd Expense Q3 2025 · Sep 30, 2024 $42.25M
Net Income Q3 2025 · Sep 30, 2025 −$33.35M
Net Income Q3 2025 · Sep 30, 2025 −$127.13M
Net Income Q3 2025 · Sep 30, 2024 −$23.67M
Net Income Q3 2025 · Sep 30, 2024 −$89.36M
Operating Income Q3 2025 · Sep 30, 2025 −$27.39M
Operating Income Q3 2025 · Sep 30, 2025 −$105.75M
Operating Income Q3 2025 · Sep 30, 2024 −$17.55M
Operating Income Q3 2025 · Sep 30, 2024 −$69.12M
Gross Profit Q3 2025 · Sep 30, 2025 $24.2M
Gross Profit Q3 2025 · Sep 30, 2025 $62.79M
Gross Profit Q3 2025 · Sep 30, 2024 $22.75M
Gross Profit Q3 2025 · Sep 30, 2024 $59.42M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $3.28M
Cost Of Revenue Q3 2025 · Sep 30, 2025 $9.16M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $2.45M
Cost Of Revenue Q3 2025 · Sep 30, 2024 $6.41M
Revenue Q3 2025 · Sep 30, 2025 $27.48M
Revenue Q3 2025 · Sep 30, 2025 $71.95M
Revenue Q3 2025 · Sep 30, 2024 $25.2M
Revenue Q3 2025 · Sep 30, 2024 $65.83M